is fda stopping tirzepatide Did the Ban Compounded Semaglutide and Tirzepatide? Tirzepatide - Thornton Erie Westminster

While compounded medications are not FDA-approved (because they are individually prepared, not mass-manufactured), they operate under a robust legal framework and clinical supervision

April 2025: Research found that semaglutide users had a slightly higher risk of developing a serious eye issue compared to people taking other GLP-1 RA drugs

Lancet (London, England) , 398 (10295), 143155 MOUNJARO TM (Tirzepatide) Injection, for Subcutaneous Use. Access Data FDA , Food and Drug Administration, Gorgojo-Martnez, J

However, side effects can occur, although they are rare

This connection helps regulate appetite and digestion, which semaglutide aims to influence for weight loss

The most common side effects are gastrointestinal: nausea, vomiting, diarrhoea, abdominal pain and constipation